Aveanna Healthcare Holdings Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AVAH research report →
Range $13 – $16
Price Chart
About the company
Aveanna Healthcare Holdings Inc. operates as a diverse platform for home-based care services throughout the United States. The company delivers a range of critical offerings, including private duty nursing (PDN), adult home health and hospice care, in-home pediatric therapy, and enteral nutrition services.
- CEO
- Jeffrey S. Shaner
- IPO
- 2021
- Employees
- 35,500
- HQ
- Atlanta, GA, US
Get TickerSpark's AI analysis on AVAH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.40B
- P/E
- 7.93
- Fwd P/E
- 13.15
- PEG
- 0.03
- P/S
- 0.95
- P/B
- 7.54
- EV/EBITDA
- 11.19
- Div Yield
- 0.00%
- Gross Margin
- 32.07%
- Op Margin
- 11.83%
- Net Margin
- 11.44%
- ROE
- 115.54%
- ROIC
- 15.98%
Latest fiscal year · YoY change
- Revenue
- $2.43B+20.2%
- Gross Profit
- $805.15M+26.7%
- Op Income
- $265.38M
- Net Income
- $225.03M+2159.1%
- EPS
- $1.10+2040.0%
- OCF Growth
- +285.6%
- FCF Growth
- +349.9%
- 52W High
- $14.71
- 52W Low
- $5.93
- 50D MA
- $12.82
- 200D MA
- $9.50
- Beta
- 2.01
- RSI (14)
- 33
- Avg Volume
- 2.87M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Aveanna reported another strong quarter with double-digit revenue and EBITDA growth, then raised full-year 2026 guidance as preferred payer strategy, rate wins, and Home Health momentum accelerated.· November 12, 2026
- Q3 revenue rose 11.8% to $695.5 million and adjusted EBITDA increased 25% to $100.1 million.
- All three operating segments grew year over year: Private Duty Services +11.6%, Home Health and Hospice +15.6%, and Medical Solutions +9.1%.
- Preferred payer mix kept expanding, with PDS preferred payer volumes at 65% of total MCO volumes, up from 57% at the end of 2025.
- Home Health and Hospice stayed heavily episodic, with an 80% episodic mix, 19.6% admission growth, and 24% episodic volume growth.
- Management raised 2026 guidance to revenue greater than $2.695 billion and adjusted EBITDA greater than $374 million, while also reaffirming stronger long-term organic growth targets.
Aveanna reported Q3 revenue of $695.5 million, up 11.8% year over year, and adjusted EBITDA of $100.1 million, up 25% year over year. Consolidated gross margin was $226.8 million, or 32.6%. By segment, Private Duty Services revenue was approximately $574 million (+11.6%) with gross margin of $166 million (28.9%); Home Health and Hospice revenue was approximately $72.1 million (+15.6%) with gross margin of 53.3%; and Medical Solutions revenue was $49.2 million (+9.1%) with gross margin of $22.3 million (45.2%). Year to date, cash from operating activities was $157.5 million and free cash flow was positive $141.2 million. Liquidity at quarter end was $492 million, including $198 million of cash, $69 million of securitization availability and $226 million of revolver availability. Management raised full-year 2026 guidance to revenue greater than $2.695 billion and adjusted EBITDA greater than $374 million.
Jeff Shaner framed the quarter as evidence that Aveanna is exiting the year with strong momentum, driven by rate improvements, preferred payer execution, and better labor trends. He emphasized that demand for home and community-based care remains strong and that the company is aligning capacity toward payers willing to support enhanced reimbursement and value-based agreements. He also highlighted progress on California PDN rates, Family First integration, and the company’s long-term plan to pursue both organic growth and tuck-in M&A. His tone was confident and upbeat, though he repeatedly noted that California still needs a permanent solution before wage pass-through can fully occur.
Matt Buckhalter focused on the strength of the quarter’s financial performance and the balance sheet. He cited Q3 revenue of $695.5 million, adjusted EBITDA of $100.1 million, consolidated gross margin of 32.6%, and segment gross margins of 28.9% in PDS, 53.3% in Home Health and Hospice, and 45.2% in Medical Solutions. He also pointed to liquidity of $492 million, cash of $198 million, and approximately $1.52 billion of variable rate debt, with $1.4 billion hedged and effectively all variable rate debt hedged through December 2029 after a new cap agreement. On cash generation, he noted $157.5 million of operating cash flow and $141.2 million of free cash flow year to date, and he said the company expects additional operating and free cash flow in the remainder of 2026.
Analysts mainly focused on 2027 outlook, California rate interpretation, Home Health momentum, and whether Q4 would imply a sequential decline. Management said it was too early to discuss 2027 specifics, but expressed confidence in the momentum carrying into next year and said the same core strategies will remain in place. On California, management said DHCS is treating the funding as a supplemental payment, while Aveanna believes the legislative intent was for a permanent rate increase; they said they are not passing through meaningful base wage increases until there is certainty about permanency. On Home Health, management said the strong growth was organic, tied to better execution and an 80% episodic mix, and that Q4 should still be strong but not at the same Q3 growth rate.
The company delivered broad-based growth across all three segments while improving margins and cash generation, which supports the case that its preferred payer and rate strategy is working. Management also sounded increasingly confident that state and federal reimbursement trends, especially in California and Home Health, could support higher long-term organic growth rates and continued M&A activity.
A key risk remains California, where the company still does not have clarity on whether the new PDN funding will become a permanent rate increase or just a temporary supplemental payment. Management also warned that Q4 will face normal holiday season choppiness and the comparison will be affected by last year’s extra week, while acknowledging that Home Health’s recent 20%+ organic growth pace is not likely sustainable indefinitely.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 21.6%
- Shares Outstanding
- 218.41M
- Float Shares
- 47.23M
of shares held by institutions
223 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bain Capital Investors LLC | 81.60M | 0 |
| Blackrock, Inc. | 8.27M | ▲ 855.10K |
| Fmr LLC | 7.80M | ▲ 6.26M |
| Nut Tree Capital Management, LP | 6.24M | ▼ 6.69M |
| Vanguard Group Inc | 5.58M | ▲ 1.54M |
| Ophir Asset Management Pty Ltd | 4.92M | ▼ 179.75K |
| Vanguard Capital Management LLC | 4.90M | ▲ 1.23M |
| Marshall Wace, Llp | 4.81M | ▲ 4.81M |
| Arrowstreet Capital, Limited Partnership | 3.92M | ▲ 2.24M |
| Braidwell LP | 3.87M | ▲ 805.00K |
| Hood River Capital Management LLC | 3.55M | ▲ 3.55M |
| Dimensional Fund Advisors LP | 3.51M | ▲ 1.25M |
Held by 256 ETFs
Biggest fund positions in AVAH by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Stewart Deborah | other | 75,000 |
| Aug 20, 26 | J.H. Whitney Equity Partners VII, LLC | sell | 957,918 |
| Aug 21, 26 | J.H. Whitney Equity Partners VII, LLC | sell | 2,250,000 |
| Aug 20, 26 | J.H. Whitney Equity Partners VII, LLC | sell | 1,426,034 |
| Aug 20, 26 | J.H. Whitney Equity Partners VII, LLC | sell | 10,112,125 |
| Aug 20, 26 | WILLIAMS ROBERT M JR | sell | 957,918 |
| Aug 21, 26 | WILLIAMS ROBERT M JR | sell | 2,250,000 |
| Aug 20, 26 | WILLIAMS ROBERT M JR | sell | 190,130 |
| Aug 20, 26 | WILLIAMS ROBERT M JR | sell | 10,112,125 |
| Aug 20, 26 | WILLIAMS ROBERT M JR | sell | 1,813,795 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AVAH coverage
Recent articles, reports, and earnings notes.
No research on AVAH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AVAH report →Healthcare Stocks Overtake Tech: 5 Strong Buys Combining Growth And Value
seekingalpha.com · Nov 17
Aveanna Healthcare: Q3 Beat And Higher Guidance Back Strong Buy Rating
seekingalpha.com · Nov 13
Should Value Investors Buy Aveanna Healthcare (AVAH) Stock?
zacks.com · Nov 13
Aveanna Healthcare: Revenue Growth, Guidance Raises, Yet Shares Still Trade At A Discount
seekingalpha.com · Nov 12
Aveanna Healthcare Holdings Inc. (AVAH) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 12
Aveanna Healthcare Just Keeps Raising The Bar
seekingalpha.com · Nov 12
What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call
marketbeat.com · Nov 12
Compared to Estimates, Aveanna (AVAH) Q3 Earnings: A Look at Key Metrics
zacks.com · Nov 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.